We are live on ! Find out more
ADMA icon

ADMA Biologics
ADMA

58 hedge funds and large institutions have $165M invested in ADMA Biologics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 23 increasing their positions, 12 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

92% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 12

60% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 5

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

44% more capital invested

Capital invested by funds: $115M → $165M (+$50.3M)

5% more funds holding

Funds holding: 55 → 58 (+3)

2.41% more ownership

Funds ownership: 55.09% → 57.5% (+2.4%)

Holders
58
Holders Change
+3
Holders Change %
+5.45%
% of All Funds
1.32%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.07%
New
8
Increased
23
Reduced
12
Closed
5
Calls
$5K
Puts
–
Net Calls
+$5K
Net Calls Change
+$5K

Top Buyers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
+$6.99M
2
CCM
Consonance Capital Management
New York
+$1.67M
3
PVI
Pura Vida Investments
New York
+$1.42M
4
Renaissance Technologies
Renaissance Technologies
New York
+$916K
5
JP Morgan Chase
JP Morgan Chase
New York
+$466K

Top Sellers

Rank Fund Capital Flow
1
SCM
Stonepine Capital Management
Oregon
-$3.75M
2
Millennium Management
Millennium Management
New York
-$1.03M
3
6CM
683 Capital Management
New York
-$461K
4
PAG
Private Advisor Group
New Jersey
-$226K
5
SIM
Spark Investment Management
New York
-$168K

ADMA Hedge Fund Activity: Q3 2018 in Review

58 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in ADMA Biologics (ADMA) for Q3 2018, worth a combined $165M — up 44% from $115M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new ADMA positions and 5 closed out — a net gain of 3 holders — while 23 added to existing stakes and 12 trimmed.

The largest buyer was Broadfin Capital, adding an estimated $6.99M. The largest seller was Stonepine Capital Management, exiting entirely with an estimated $3.75M sold.

  • 58 institutional investors held ADMA Biologics (ADMA) as of Q3 2018, up from 55 in Q2 2018.
  • Funds reported $165M of ADMA Biologics stock for Q3 2018, up 44% quarter-over-quarter.
  • 8 funds opened new ADMA Biologics positions in Q3 2018 and 5 closed out, a net change of +3 holders.
  • The largest ADMA Biologics buyer in Q3 2018 was Broadfin Capital, an estimated $6.99M added.
  • The largest ADMA Biologics seller in Q3 2018 was Stonepine Capital Management, an estimated $3.75M sold.

Based on aggregated 13F filings for Q3 2018.